Cargando…

Therapeutics of Alzheimer’s Disease: Recent Developments

With increasing aging, dementia is a growing public health concern globally. Patients with dementia have multiple psychological and behavioral changes, including depression, anxiety, inappropriate behavior, paranoia, agitation, and hallucinations. The major types of dementia are Alzheimer’s disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Burns, Scott, Selman, Ashley, Sehar, Ujala, Rawat, Priyanka, Reddy, Arubala P., Reddy, P. Hemachandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774459/
https://www.ncbi.nlm.nih.gov/pubmed/36552610
http://dx.doi.org/10.3390/antiox11122402
_version_ 1784855413212053504
author Burns, Scott
Selman, Ashley
Sehar, Ujala
Rawat, Priyanka
Reddy, Arubala P.
Reddy, P. Hemachandra
author_facet Burns, Scott
Selman, Ashley
Sehar, Ujala
Rawat, Priyanka
Reddy, Arubala P.
Reddy, P. Hemachandra
author_sort Burns, Scott
collection PubMed
description With increasing aging, dementia is a growing public health concern globally. Patients with dementia have multiple psychological and behavioral changes, including depression, anxiety, inappropriate behavior, paranoia, agitation, and hallucinations. The major types of dementia are Alzheimer’s disease (AD), vascular dementia (VCID), Lewy body dementia (LBD), frontotemporal dementia (FTD), and mixed dementia (MiAD). Among these, AD is the most common form of dementia in the elderly population. In the last three decades, tremendous progress has been made in understanding AD’s biology and disease progression, particularly its molecular basis, biomarker development, and drug discovery. Multiple cellular changes have been implicated in the progression of AD, including amyloid beta, phosphorylated tau, synaptic damage, mitochondrial dysfunction, deregulated microRNAs, inflammatory changes, hormonal deregulation, and others; based on these changes, therapeutic strategies have been developed, which are currently being tested in animal models and human clinical trials. The purpose of our article is to highlight recent therapeutic strategies’ developments, critically discuss current strategies’ failures, and propose new strategies to combat this devasting mental illness.
format Online
Article
Text
id pubmed-9774459
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97744592022-12-23 Therapeutics of Alzheimer’s Disease: Recent Developments Burns, Scott Selman, Ashley Sehar, Ujala Rawat, Priyanka Reddy, Arubala P. Reddy, P. Hemachandra Antioxidants (Basel) Review With increasing aging, dementia is a growing public health concern globally. Patients with dementia have multiple psychological and behavioral changes, including depression, anxiety, inappropriate behavior, paranoia, agitation, and hallucinations. The major types of dementia are Alzheimer’s disease (AD), vascular dementia (VCID), Lewy body dementia (LBD), frontotemporal dementia (FTD), and mixed dementia (MiAD). Among these, AD is the most common form of dementia in the elderly population. In the last three decades, tremendous progress has been made in understanding AD’s biology and disease progression, particularly its molecular basis, biomarker development, and drug discovery. Multiple cellular changes have been implicated in the progression of AD, including amyloid beta, phosphorylated tau, synaptic damage, mitochondrial dysfunction, deregulated microRNAs, inflammatory changes, hormonal deregulation, and others; based on these changes, therapeutic strategies have been developed, which are currently being tested in animal models and human clinical trials. The purpose of our article is to highlight recent therapeutic strategies’ developments, critically discuss current strategies’ failures, and propose new strategies to combat this devasting mental illness. MDPI 2022-12-03 /pmc/articles/PMC9774459/ /pubmed/36552610 http://dx.doi.org/10.3390/antiox11122402 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Burns, Scott
Selman, Ashley
Sehar, Ujala
Rawat, Priyanka
Reddy, Arubala P.
Reddy, P. Hemachandra
Therapeutics of Alzheimer’s Disease: Recent Developments
title Therapeutics of Alzheimer’s Disease: Recent Developments
title_full Therapeutics of Alzheimer’s Disease: Recent Developments
title_fullStr Therapeutics of Alzheimer’s Disease: Recent Developments
title_full_unstemmed Therapeutics of Alzheimer’s Disease: Recent Developments
title_short Therapeutics of Alzheimer’s Disease: Recent Developments
title_sort therapeutics of alzheimer’s disease: recent developments
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774459/
https://www.ncbi.nlm.nih.gov/pubmed/36552610
http://dx.doi.org/10.3390/antiox11122402
work_keys_str_mv AT burnsscott therapeuticsofalzheimersdiseaserecentdevelopments
AT selmanashley therapeuticsofalzheimersdiseaserecentdevelopments
AT seharujala therapeuticsofalzheimersdiseaserecentdevelopments
AT rawatpriyanka therapeuticsofalzheimersdiseaserecentdevelopments
AT reddyarubalap therapeuticsofalzheimersdiseaserecentdevelopments
AT reddyphemachandra therapeuticsofalzheimersdiseaserecentdevelopments